Nightmares & Disorders
Narcolepsy: the sleep disorder that is usually diagnosed a decade late
It is caused by the loss of about 20,000 neurons that produce a single neurotransmitter, it is probably autoimmune, and its most distinctive symptom is routinely mistaken for something psychiatric.
Narcolepsy affects roughly 1 in 2,000 people. The median delay between symptom onset and diagnosis has been reported at around eight to ten years, and many patients see multiple specialists first — psychiatrists, neurologists, endocrinologists — before anyone orders a sleep study.
Onset is typically in adolescence or early adulthood, which is precisely when excessive sleepiness is easiest to attribute to lifestyle.
The cause
Narcolepsy type 1 is caused by the loss of neurons in the lateral hypothalamus that produce orexin, also called hypocretin — a neuropeptide discovered independently by two groups in 1998. There are only around 50,000 to 80,000 such neurons in a human brain, and in narcolepsy type 1 the great majority are gone.
Orexin stabilises the boundary between sleep and wakefulness. Without it, the states become unstable and intrude on each other — REM phenomena appear during wakefulness, and wakefulness fragments sleep.
The evidence points strongly to an autoimmune mechanism. Nearly all patients carry the HLA-DQB1*06:02 allele. Onset frequently follows infection, particularly streptococcal infection and influenza. And there was a striking increase in cases following the 2009 H1N1 pandemic, associated both with infection and, in some European countries, with the Pandemrix vaccine — an association investigated extensively and accepted in several national reviews.
The five symptoms
Excessive daytime sleepiness is universal and is the presenting complaint. It is not ordinary tiredness — it is an overwhelming pressure to sleep, sometimes irresistible, occurring in inappropriate situations. Short naps are typically refreshing, which distinguishes it from the sleepiness of depression or sleep apnoea.
Cataplexy is the most specific symptom and the one most often misread. It is a sudden, brief loss of muscle tone triggered by strong emotion — most characteristically laughter, but also surprise, anger or excitement. Consciousness is fully preserved. It may be subtle: a sagging jaw, head nod, buckling knees, slurred speech. Or it may involve complete collapse.
Cataplexy is REM atonia intruding into wakefulness. Its presence essentially confirms narcolepsy type 1. It is frequently diagnosed as syncope, seizures, or a functional or psychiatric disorder, and patients are sometimes told it is attention-seeking.
Sleep paralysis — REM atonia persisting into waking.
Hypnagogic and hypnopompic hallucinations — vivid, often frightening dream imagery at sleep onset or on waking. These are commonly mistaken for psychosis, and patients have been treated with antipsychotics as a result.
Disrupted night-time sleep. Counter-intuitively, people with narcolepsy sleep badly at night — fragmented, with frequent awakenings. Total sleep across twenty-four hours is often normal; it is the organisation that has failed.
Sleepiness in a teenager is attributed to phones, late nights or laziness. Cataplexy is described by patients in terms that do not sound neurological — "I go weak when I laugh" — and is rarely asked about directly. Hallucinations get filed as psychiatric. And the condition is rare enough that most clinicians will see very few cases.
Diagnosis
Overnight polysomnography followed by a multiple sleep latency test the next day: five nap opportunities at two-hourly intervals. Mean sleep latency of eight minutes or less, with two or more sleep-onset REM periods, supports the diagnosis. A REM period occurring within fifteen minutes of sleep onset on the preceding night's study can count as one.
The test requires careful preparation — adequate sleep beforehand, and withdrawal of REM-suppressing medications, particularly antidepressants, which otherwise produce false negatives.
Cerebrospinal fluid orexin measurement is the most specific test: a level below 110 pg/mL is diagnostic of type 1. It requires a lumbar puncture and is not used routinely.
Narcolepsy type 2 has the sleepiness and the sleep study findings but no cataplexy and normal orexin, and its boundaries are less clear.
Treatment
There is no cure. Symptom control is generally good.
For sleepiness: modafinil and armodafinil are usual first-line. Solriamfetol and pitolisant are newer options — pitolisant is a histamine H3 antagonist, working through a different mechanism and also helping cataplexy. Traditional stimulants such as methylphenidate and amfetamines remain effective.
For cataplexy: sodium oxybate, taken in two doses during the night, is the most effective single agent and also improves night-time sleep and daytime sleepiness. It is tightly controlled and has a demanding dosing schedule. Lower-sodium formulations are now available. Antidepressants — venlafaxine, clomipramine, SSRIs — suppress cataplexy through REM suppression, and abrupt withdrawal can cause severe rebound.
Scheduled naps. Two or three planned short naps a day are genuinely effective and reduce medication requirements. This is underused, largely because it requires accommodation at work or school.
Orexin receptor agonists are in clinical trials and represent the first prospect of treating the cause rather than the symptoms. Early results have been notable.
Living with it
Driving regulations vary and generally require symptom control. Employers and schools in many jurisdictions have legal obligations to make reasonable adjustments, including scheduled naps.
The under-discussed part is the psychological cost of years of being told you are lazy, dramatic or unwell in some vaguer way. Rates of depression are elevated in narcolepsy, and some of that is likely the disorder and some of it is the decade before anyone believed the symptoms were real.
